NASDAQ
38.60USD
+3.49 (+9.94%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
4.3B
P/E
—
EPS
—
Beta
-0.20
52W range
7.96-39.07
Day range
35.32–39.06
Open
36.11
Prev close
35.11
Volume
8.2M
Avg volume
1.7M
Dividend
1.02
IPO
2022-01-07
https://www.businesswire.com/news/home/20260819148986/en/Amylyx-Pharmaceuticals-Announces-Pricing-of-an-Upsized-500-Million-Underwritten-Public-Offering-of-Common-Stock/ · 8/20/2026+0.20
https://www.businesswire.com/news/home/20260608097177/en/Amylyx-Pharmaceuticals-Announces-Poster-Presentations-at-ENDO-2026/ · 6/8/2026+0.20
https://www.marketbeat.com/instant-alerts/amylyx-pharmaceuticals-eyes-phase-3-avexitide-readout-as-2027-launch-comes-into-focus-2026-05-14/ · 5/14/2026+0.60
https://www.prnewswire.com/news-releases/did-amylyx-pharmaceuticals-inc-insiders-breach-their-fiduciary-duties-to-shareholders-302738798.html · 4/9/2026-0.50
https://www.prnewswire.com/news-releases/did-archer-daniels-midland-company-insiders-breach-their-fiduciary-duties-to-shareholders-302738797.html · 4/9/2026-0.50
https://www.defenseworld.net/2026/03/15/437391-shares-in-amylyx-pharmaceuticals-inc-amlx-purchased-by-ally-bridge-group-ny-llc.html · 3/15/2026+0.20
https://seekingalpha.com/article/4878531-amylyx-lucidity-trial-sets-stage-for-q3-inflection-point · 3/4/2026-0.20
https://www.fool.com/coverage/filings/2026/01/31/amylyx-pharmaceuticals-co-chief-executive-sells-amlx-138k-shares-for-usd1-9-million/ · 2/1/2026-0.20
https://www.businesswire.com/news/home/20251111312207/en/Rosen-Law-Firm-Announces-Investigation-of-Breaches-of-Fiduciary-Duties-by-the-Directors-and-Officers-of-Amylyx-Pharmaceuticals-Inc.-%E2%80%93-AMLX/ · 11/11/2025-0.80
https://www.zacks.com/stock/news/2788511/is-exact-sciences-exas-stock-outpacing-its-medical-peers-this-year?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_1-2788511 · 11/10/2025+0.80
https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-amylyx-pharmaceuticals-inc-to-contact-law-firm-302591570.html · 10/22/2025-1.00
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
